A43D720D-0CA3-48CF-ADC7-5AC72BD5EEA9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.603
- MYC_TARGETS_V1+0.552
- IL6_JAK_STAT3_SIGNALING+0.546
- G2M_CHECKPOINT+0.496
- ALLOGRAFT_REJECTION+0.488
- INTERFERON_GAMMA_RESPONSE+0.484
- DNA_REPAIR+0.477
- TNFA_SIGNALING_VIA_NFKB+0.476
- MTORC1_SIGNALING+0.443
- INFLAMMATORY_RESPONSE+0.437
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.362
- KRAS_SIGNALING_DN-0.344
- MYOGENESIS-0.281
- APICAL_SURFACE-0.216
- UV_RESPONSE_DN-0.186
- WNT_BETA_CATENIN_SIGNALING-0.173
- ESTROGEN_RESPONSE_EARLY-0.167
- APICAL_JUNCTION-0.129
- BILE_ACID_METABOLISM-0.120
- SPERMATOGENESIS-0.116
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | CA6E11F4-8B85-4C73-9B48-C28F5D5D91D6 | — | — | 0.976 |
| 2 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.971 |
| 3 | AB5294B5-4A59-493A-9016-C2778735745F | — | — | 0.965 |
| 4 | E92DD0CC-DD0F-469D-8357-228A4A67DBD6 | — | — | 0.965 |
| 5 | 3E499D12-B08A-491C-98C6-19EA420BDC99 | — | — | 0.960 |
| 6 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.959 |
| 7 | FFECD0E9-70C2-44BD-B0B4-E8C4B60B793A | — | — | 0.956 |
| 8 | 4A54E284-9902-4E4C-A5BC-1BF144106EA3 | — | — | 0.955 |
| 9 | FCD3124F-0F41-448E-B2B9-D9934D4EC1A7 | — | — | 0.955 |
| 10 | AF548E30-7121-4F9F-A2CD-F1A540E9C4EE | — | — | 0.955 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.603 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.552 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.546 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.496 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.488 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.484 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.477 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.476 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.443 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.437 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.433 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.392 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.391 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.386 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.373 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.365 | Inavolisib | — uncovered |
| HYPOXIA | 0.356 | Idelalisib | — uncovered |
| APOPTOSIS | 0.351 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.334 | Idelalisib | — uncovered |